EKSO BIONICS HOLDINGS, INC. (EKSO)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 2,057 | 3,375 | 4,129 | |
| Cost of revenue | 1,238 | 1,569 | 1,920 | |
| Gross profit | 819 | 1,806 | 2,209 | |
| Sales and marketing | 1,690 | 1,707 | 1,760 | |
| Research and development | 852 | 988 | 777 | |
| General and administrative | 2,252 | 2,551 | 2,311 | |
| Total operating expenses | 4,794 | 5,246 | 4,848 | |
| Loss from operations | -3,975 | - | -2,639 | |
| Other expense, net | -8 | -6 | -2 | |
| Interest expense, net | 65 | 72 | 79 | |
| Unrealized gain (loss) on foreign exchange | 1,339 | 626 | 634 | |
| Gain on revaluation of warrant liabilities | - | 1 | 14 | |
| Loss on modification of warrant | - | - | - | |
| Total other income (expense), net | 1,266 | 549 | 567 | |
| Net loss | -2,709 | -2,891 | -2,072 | |
| Other comprehensive (loss) income | -1,107 | -533 | -527 | |
| Comprehensive loss | -3,816 | -3,424 | -2,599 | |
| Diluted average shares | - | - | 20,310,000 | |
| Net loss per share applicable to common stockholders, basic and diluted (in dollars per share) | -1.24 | -0.12 | -0.1 | |
| Us-gaap_earningspersharediluted | -1.24 | -0.12 | -0.1 | |
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 2,180,000 | 25,393,000 | 20,310,000 | |